Comparative Pharmacology
Head-to-head clinical analysis: PIMOZIDE versus PROCHLORPERAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PIMOZIDE versus PROCHLORPERAZINE.
PIMOZIDE vs PROCHLORPERAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Blocks dopamine D2, D3, and D4 receptors; also 5-HT2A, α1-adrenergic, and H1 receptors.
Prochlorperazine is a phenothiazine antipsychotic that acts as a dopamine D2 receptor antagonist in the chemoreceptor trigger zone (CTZ) and at high doses in the mesolimbic system. It also has anticholinergic and antiemetic effects.
1-10 mg orally once daily; maximum 10 mg/day.
5-10 mg IM/IV every 3-4 hours as needed; or 5-10 mg PO 3-4 times daily; or 25 mg PR twice daily. Maximum IM/IV: 40 mg/day; PO: 40 mg/day.
MODERATE Risk
MODERATE Risk
Terminal elimination half-life is approximately 50-60 hours in adults; may be prolonged in elderly or hepatic impairment.
Clinical Note
moderatePimozide + Levofloxacin
"Pimozide may increase the QTc-prolonging activities of Levofloxacin."
Clinical Note
moderatePimozide + Norfloxacin
"Pimozide may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderatePimozide + Gemifloxacin
"Pimozide may increase the QTc-prolonging activities of Gemifloxacin."
Clinical Note
moderatePimozide + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Pimozide is combined with Fluticasone propionate."
Terminal elimination half-life: 23-25 hours, with prolonged elimination in hepatic impairment.
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 70-90% of eliminated drug; fecal excretion ~10-30%.
Renal: 70-80% (as metabolites), Fecal: 20-30% (unchanged and metabolites), Biliary: 10-15% of dose excreted in bile.
Category A/B
Category A/B
Typical Antipsychotic
Typical Antipsychotic / Antiemetic